Nothing Special   »   [go: up one dir, main page]

EA201591353A1 - Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента - Google Patents

Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента

Info

Publication number
EA201591353A1
EA201591353A1 EA201591353A EA201591353A EA201591353A1 EA 201591353 A1 EA201591353 A1 EA 201591353A1 EA 201591353 A EA201591353 A EA 201591353A EA 201591353 A EA201591353 A EA 201591353A EA 201591353 A1 EA201591353 A1 EA 201591353A1
Authority
EA
Eurasian Patent Office
Prior art keywords
particles
improvement
application
pharmaceutical agent
solid media
Prior art date
Application number
EA201591353A
Other languages
English (en)
Inventor
Джоанна М. Козиара
Марк М. Меннинг
Реза Олияй
Роберт Г. Стрикли
Ричард Йу
Брайан П. Кирни
Анита А. Матиас
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40809930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591353(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201591353A1 publication Critical patent/EA201591353A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Согласно изобретению предложена композиция, содержащая соединение формулы (I)или его фармацевтически приемлемая соль, и множество частиц твердого носителя, а также способы применения композиции для ингибирования активности цитохрома Р-450.
EA201591353A 2008-05-02 2009-05-01 Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента EA201591353A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4993508P 2008-05-02 2008-05-02
US15065209P 2009-02-06 2009-02-06
US15065509P 2009-02-06 2009-02-06

Publications (1)

Publication Number Publication Date
EA201591353A1 true EA201591353A1 (ru) 2016-01-29

Family

ID=40809930

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201591353A EA201591353A1 (ru) 2008-05-02 2009-05-01 Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
EA201071173A EA022950B1 (ru) 2008-05-02 2009-05-01 Применение частиц носителя диоксида кремния для улучшения технологических характеристик фармацевтического агента

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201071173A EA022950B1 (ru) 2008-05-02 2009-05-01 Применение частиц носителя диоксида кремния для улучшения технологических характеристик фармацевтического агента

Country Status (27)

Country Link
US (1) US10039718B2 (ru)
EP (2) EP3006032A1 (ru)
JP (2) JP5722213B2 (ru)
KR (2) KR101659971B1 (ru)
CN (3) CN104940937A (ru)
AP (1) AP3089A (ru)
AU (3) AU2009242451C1 (ru)
BR (1) BRPI0911871A8 (ru)
CA (1) CA2720856C (ru)
CO (1) CO6321225A2 (ru)
CY (1) CY1117067T1 (ru)
DK (1) DK2296633T3 (ru)
EA (2) EA201591353A1 (ru)
EC (1) ECSP10010636A (ru)
ES (1) ES2553897T3 (ru)
HK (2) HK1153670A1 (ru)
HR (1) HRP20151357T1 (ru)
HU (1) HUE026380T2 (ru)
IL (2) IL208614A (ru)
MX (2) MX2010011963A (ru)
NZ (1) NZ588978A (ru)
PL (1) PL2296633T3 (ru)
PT (1) PT2296633E (ru)
SG (2) SG190618A1 (ru)
SI (1) SI2296633T1 (ru)
WO (1) WO2009135179A2 (ru)
ZA (1) ZA201008007B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101636221B1 (ko) 2006-07-07 2016-07-04 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
CN101679325B (zh) * 2007-02-23 2013-08-28 吉里德科学公司 治疗剂的药代动力学特性调节剂
TW200916103A (en) * 2007-06-29 2009-04-16 Gilead Sciences Inc Therapeutic compositions and methods
US20090093467A1 (en) * 2007-06-29 2009-04-09 Gilead Sciences, Inc. Therapeutic compositions and methods
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
MY185604A (en) 2010-11-19 2021-05-25 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012151165A1 (en) 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
US20140142070A1 (en) * 2011-07-07 2014-05-22 Janssen R&D Ireland Darunavir combination formulations
JP5651275B2 (ja) 2011-08-16 2015-01-07 ギリアード サイエンシス インコーポレーテッド テノホビルアラフェナミドヘミフマレート
AU2013207825A1 (en) * 2012-01-12 2014-08-28 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
JP2015510509A (ja) 2012-02-03 2015-04-09 ギリアード サイエンシーズ， インコーポレイテッド 医薬品を調製するための方法および中間体
JP2015508822A (ja) 2012-03-01 2015-03-23 ギリアード サイエンシーズ， インコーポレイテッド 噴霧乾燥製剤
WO2014064409A1 (en) * 2012-10-23 2014-05-01 Cipla Limited Pharmaceutical antiretroviral composition
WO2014105777A1 (en) 2012-12-26 2014-07-03 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
DE102013205347A1 (de) 2013-03-26 2014-10-02 Hilti Aktiengesellschaft Additiv-Zusammensetzung für Amin-Härter, deren Verwendung sowie diese enthaltende Amin-Härterzusammensetzung
CN103230403A (zh) * 2013-04-23 2013-08-07 苏州谷力生物科技有限公司 一种抗艾滋病毒的组合型药物片剂
AU2014356067A1 (en) * 2013-11-29 2016-06-16 Mylan Laboratories Ltd. Amorphous cobicistat solid dispersion
WO2015145324A1 (en) * 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
TW201728582A (zh) 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
ES2952878T3 (es) 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
EA202191370A1 (ru) * 2018-12-14 2021-09-16 Фуджифилм Корпорэйшн Фармацевтическая композиция и способ ее получения
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN113425702B (zh) * 2021-06-25 2022-08-26 中国药科大学 应用微流控技术制备纳米颗粒、制备方法及装置和用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
FR2096292A5 (ru) 1970-06-15 1972-02-11 Sumitomo Chemical Co
CH586568A5 (ru) 1972-04-10 1977-04-15 Hoffmann La Roche
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4603143A (en) * 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2609958B1 (fr) 1987-01-27 1995-03-10 Honda Motor Co Ltd Dispositif de support pour roues arriere de motocyclettes
FR2631620B1 (fr) 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IE913840A1 (en) 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
CA2502856C (en) 1992-12-29 2009-01-20 Abbott Laboratories Intermediates for retroviral protease inhibiting compounds
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
JP4064476B2 (ja) * 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (ja) * 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
FR2767071B1 (fr) 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20030035834A1 (en) * 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
WO2002024167A1 (fr) * 2000-09-19 2002-03-28 Daiichi Pharmaceutical Co., Ltd. Composition medicinale
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (de) 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
AU2002236166B2 (en) * 2001-05-01 2006-12-07 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition
ES2257559T3 (es) 2001-05-18 2006-08-01 Lonza Ag Procedimiento para la preparacion de formulaciones solidas de 3-hidroxi-3-metilbutirato de sodio.
DE10126163A1 (de) * 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
BR0210867A (pt) * 2001-07-06 2004-06-29 Lifecycle Pharma As Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
EP1509204A4 (en) 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co AGGLOMERATED PARTICLES WITH AN ACTIVE SUBSTANCE PREPARED WITH MELTED MICROCRYSTALLINE CELLULOSE
US6926906B2 (en) * 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de) * 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
WO2004046115A1 (ja) 2002-11-20 2004-06-03 Japan Tobacco Inc. ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
US7189416B2 (en) * 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
BRPI0406760A (pt) 2003-01-14 2005-12-20 Gilead Sciences Inc Composições e métodos para terapia antiviral de combinação
CN1758901B (zh) * 2003-02-19 2010-04-28 生命周期药物公司 硅石或硅石衍生物作为吸附材料的用途
EP1601347A1 (en) 2003-02-19 2005-12-07 LifeCycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
JP4018664B2 (ja) 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
DE10337198A1 (de) * 2003-08-13 2005-03-17 Degussa Ag Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
US20070122482A1 (en) * 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
WO2005034908A2 (en) 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
WO2005084670A1 (en) * 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Pharmaceutical formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
BRPI0512660A (pt) 2004-06-28 2008-04-01 Lifecycle Pharma As tablete carregável, e, método para a preparação de um tablete
US20060009603A1 (en) * 2004-07-09 2006-01-12 David Young Fibrillation-resistant polypropylene tape
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
JP2007039338A (ja) 2005-07-29 2007-02-15 Hirofumi Takeuchi シリカ系複合顆粒
CA2633603C (en) 2005-12-14 2016-09-13 Cipla Limited Pharmaceutical combination
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
DK1973529T3 (da) 2006-01-05 2011-09-12 Veloxis Pharmaceuticals As Fyldbar tablet, som er i stand til at falde hen
KR20080110993A (ko) * 2006-02-20 2008-12-22 아사히비루 가부시키가이샤 과립, 정제 및 그들의 제조방법
MX2008012225A (es) * 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
KR101636221B1 (ko) * 2006-07-07 2016-07-04 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
WO2008017867A2 (en) 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition with at least one water insoluble polymer
WO2008029417A2 (en) * 2006-09-04 2008-03-13 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
CN101679325B (zh) * 2007-02-23 2013-08-28 吉里德科学公司 治疗剂的药代动力学特性调节剂
US20090093467A1 (en) 2007-06-29 2009-04-09 Gilead Sciences, Inc. Therapeutic compositions and methods
TW200916103A (en) 2007-06-29 2009-04-16 Gilead Sciences Inc Therapeutic compositions and methods
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
PT2393485E (pt) * 2009-02-06 2015-10-23 Gilead Sciences Inc Comprimidos bicamada que compreendem elvitegravir, cobicistat, emtricitabina e tenofovir
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
TW201728582A (zh) 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型

Also Published As

Publication number Publication date
AP3089A (en) 2015-01-31
JP2014012741A (ja) 2014-01-23
HUE026380T2 (en) 2016-06-28
PL2296633T3 (pl) 2016-03-31
HRP20151357T1 (hr) 2016-01-29
EP2296633A2 (en) 2011-03-23
EP2296633B1 (en) 2015-09-30
AU2009242451A1 (en) 2009-11-05
NZ588978A (en) 2013-01-25
ES2553897T3 (es) 2015-12-14
SG10201609006WA (en) 2016-12-29
JP2011522790A (ja) 2011-08-04
ZA201008007B (en) 2011-10-26
CN102123700A (zh) 2011-07-13
MX342377B (es) 2016-09-27
KR101659971B1 (ko) 2016-09-26
CA2720856A1 (en) 2009-11-05
CN104940937A (zh) 2015-09-30
AU2014221210B2 (en) 2016-08-18
WO2009135179A2 (en) 2009-11-05
CO6321225A2 (es) 2011-09-20
JP5925171B2 (ja) 2016-05-25
CY1117067T1 (el) 2017-04-05
BRPI0911871A8 (pt) 2018-03-06
AU2016250470A1 (en) 2016-11-17
KR20110015581A (ko) 2011-02-16
PT2296633E (pt) 2015-12-04
WO2009135179A3 (en) 2011-05-19
DK2296633T3 (en) 2016-01-11
BRPI0911871A2 (pt) 2015-11-17
EA201071173A1 (ru) 2011-08-30
CN103479584A (zh) 2014-01-01
AP2010005429A0 (en) 2010-10-31
US20090324729A1 (en) 2009-12-31
US10039718B2 (en) 2018-08-07
ECSP10010636A (es) 2011-03-31
MX2010011963A (es) 2010-12-06
HK1215679A1 (zh) 2016-09-09
EA022950B1 (ru) 2016-03-31
AU2014221210C1 (en) 2017-06-01
EP3006032A1 (en) 2016-04-13
CA2720856C (en) 2016-02-02
IL208614A0 (en) 2010-12-30
SG190618A1 (en) 2013-06-28
HK1153670A1 (zh) 2012-04-05
KR20160114728A (ko) 2016-10-05
IL208614A (en) 2016-09-29
KR101784647B1 (ko) 2017-10-11
JP5722213B2 (ja) 2015-05-20
AU2009242451C1 (en) 2017-05-18
SI2296633T1 (sl) 2015-11-30
IL247417A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
EA201071173A1 (ru) Применение частиц твёрдого носителя для улучшения технологических характеристик фармацевтического агента
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
EA200700138A1 (ru) Замещённые индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
MX2013006802A (es) Inhibidores de neprilisina.
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MY170935A (en) Neprilysin inhibitors
EA200970156A1 (ru) Пиридизиноновые производные
MY165087A (en) Neprilysin inhibitors
PH12016502037A1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
EA200870599A1 (ru) Стабильные препараты лаквинимода
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
EA201101026A1 (ru) Ингибиторы бета-секретазы
MX342212B (es) Inhibidores de neprilisina.
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201291073A1 (ru) Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
CY1109331T1 (el) Παραγωγα αμινοφαινυλιου ως νεοι αναστολεις της αποακετυλασης ιστονης
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201070635A1 (ru) Соединения, ингибирующие дипептидилпептидазу-iv,способы их получения и фармацевтические композиции, содержащие их в качестве активного агента
MY151986A (en) Adamantyl diamide derivatives and uses of same
EA201270590A1 (ru) Ингибиторы акт
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak